Literature DB >> 33259744

Triglyceride Glucose Index and Related Parameters (Triglyceride Glucose-Body Mass Index and Triglyceride Glucose-Waist Circumference) Identify Nonalcoholic Fatty Liver and Liver Fibrosis in Individuals with Overweight/Obesity.

Mohammad E Khamseh1, Mojtaba Malek2, Rowshanak Abbasi1, Hoda Taheri1, Maryam Lahouti1, Fariba Alaei-Shahmiri1.   

Abstract

Background: The triglyceride glucose (TyG) index has been proposed as a reliable surrogate marker for nonalcoholic fatty liver disease (NAFLD). Furthermore, NAFLD is strongly related with obesity. This study aimed to compare TyG index and its related parameters (TyG-waist circumference [WC] and TyG-body mass index [BMI]), comprising TyG and obesity markers, in predicting NAFLD and liver fibrosis in overweight/obese individuals without diabetes.
Methods: This was a cross-sectional study consisting of 184 overweight/obese people (96 with and 88 without NAFLD), 30-65 years of age. TyG, TyG-BMI, and TyG-WC were computed using the established formula. Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were determined by transient elastography (FibroScan).
Results: In correlation analyses, CAP and LSM were significantly associated with WC, BMI, TyG, TyG-BMI, and TyG-WC. Regression analyses highlighted TyG-WC as a significant predictor of NAFLD, with the highest standardized odds ratio (2.25, P < 0.001); while liver fibrosis was associated more strongly with TyG-BMI. In receiver operating characteristic (ROC) analysis, TyG-WC showed the largest area under the ROC curve (AUC) for detection of NAFLD (0.693, 95% confidence interval [CI]: 0.617-0.769). However, TyG-BMI was a better discriminator of liver fibrosis (AUC: 0.635, 95% CI: 0.554-0.714). TyG-WC value of 876 (sensitivity: 81.3%, specificity: 52.3%) and TyG-BMI value of 259 (sensitivity: 78.3%, specificity: 51.3%) were the optimal cutoff points to predict NAFLD and liver fibrosis, respectively. Conclusions: The results highlight the significant associations of TyG and its related indices with NAFLD, with TyG-WC being a better indicator. TyG-BMI and TyG-WC could reliably predict liver fibrosis in this population. These indices appear to be simple, practical, and affordable tools for screening NAFLD and liver fibrosis in clinical settings.

Entities:  

Keywords:  NAFLD; TyG; TyG-BMI; TyG-WC; liver fibrosis; nonalcoholic fatty liver disease; obesity

Mesh:

Substances:

Year:  2020        PMID: 33259744     DOI: 10.1089/met.2020.0109

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  17 in total

1.  The triglyceride-glucose index as a clinical useful marker for metabolic associated fatty liver disease (MAFLD): a population-based study among Iranian adults.

Authors:  Ehsaneh Taheri; Mohammad Amin Pourhoseingholi; Alireza Moslem; Amir Hossein Hassani; Alireza Mousavi Jarrahi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali; Behzad Hatami
Journal:  J Diabetes Metab Disord       Date:  2022-01-11

2.  TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients.

Authors:  Jianqi Zhao; Hongxuan Fan; Ting Wang; Bing Yu; Shaobin Mao; Xun Wang; Wenjing Zhang; Leigang Wang; Yao Zhang; Zhaoyu Ren; Bin Liang
Journal:  Cardiovasc Diabetol       Date:  2022-07-01       Impact factor: 8.949

3.  Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study.

Authors:  Zhi Liu; He He; Yuzhao Dai; Lidan Yang; Shenling Liao; Zhenmei An; Shuangqing Li
Journal:  Lipids Health Dis       Date:  2022-06-25       Impact factor: 4.315

4.  Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study.

Authors:  Ru Zhang; Qing Guan; Mengting Zhang; Yajie Ding; Zongzhe Tang; Hongliang Wang; Wei Zhang; Yue Chen; Rong Jiang; Yan Cui; Jie Wang
Journal:  Diabetes Metab Syndr Obes       Date:  2022-10-19       Impact factor: 3.249

5.  Triglyceride-Glucose Index for Early Prediction of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of 121,975 Individuals.

Authors:  Azizullah Beran; Hazem Ayesh; Mohammed Mhanna; Waseem Wahood; Sami Ghazaleh; Ziad Abuhelwa; Wasef Sayeh; Nameer Aladamat; Rami Musallam; Reem Matar; Saif-Eddin Malhas; Ragheb Assaly
Journal:  J Clin Med       Date:  2022-05-09       Impact factor: 4.964

6.  Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus.

Authors:  Mojtaba Malek; Mohammad E Khamseh; Haleh Chehrehgosha; Sohrab Nobarani; Fariba Alaei-Shahmiri
Journal:  Endocrine       Date:  2021-08-05       Impact factor: 3.633

7.  Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects.

Authors:  Hwi Seung Kim; Yun Kyung Cho; Eun Hee Kim; Min Jung Lee; Chang Hee Jung; Joong-Yeol Park; Hong-Kyu Kim; Woo Je Lee
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

8.  The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease.

Authors:  Guotai Sheng; Song Lu; Qiyang Xie; Nan Peng; Maobin Kuang; Yang Zou
Journal:  Lipids Health Dis       Date:  2021-10-10       Impact factor: 3.876

9.  Association Between the Triglyceride-Glucose Index and Outcomes of Nonalcoholic Fatty Liver Disease: A Large-Scale Health Management Cohort Study.

Authors:  Jing Liu; Liying Guan; Meng Zhao; Qihang Li; An Song; Ling Gao; Haiyan Lin; Jiajun Zhao
Journal:  Diabetes Metab Syndr Obes       Date:  2021-06-21       Impact factor: 3.168

10.  Usefulness of the triglyceride glucose-body mass index in evaluating nonalcoholic fatty liver disease: insights from a general population.

Authors:  Rongsheng Wang; Longlong Dai; Yanjia Zhong; Guobo Xie
Journal:  Lipids Health Dis       Date:  2021-07-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.